GlassScriptPhysician profile
Wayne H Fujita
NPI 1073690152
$385,217.78
in general payments reported to CMS, 2019-2025
33 companies · $79K in 2025
The $79K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $18K · 2021: $32K · 2022: $44K · 2023: $68K · 2024: $93K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $141K · Consulting Fee: $52K · Food and Beverage: $26K · Travel and Lodging: $21K · Education: $459 · Honoraria: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $140,675.00 |
| Consulting Fee | $51,700.99 |
| Food and Beverage | $25,772.40 |
| Travel and Lodging | $21,356.79 |
| Education | $458.50 |
| Honoraria | $260.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $78,523.95 | 2019-2025 | |
| Abbvie INC. | $77,174.64 | 2019-2025 | |
| Amgen INC. | $74,195.52 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $32,432.87 | 2021-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $28,492.28 | 2019-2025 | Nemluvio, Aklief |
| Celgene Corporation | $26,156.26 | 2019-2020 | |
| Leo Pharma INC. | $21,376.07 | 2021-2025 | Anzupgo, Adbry |
| Sun Pharmaceutical Industries INC. | $16,253.70 | 2019-2025 | Ilumya, Winlevi |
| Dermira, INC. | $4,672.85 | 2019-2021 | |
| Ucb, INC. | $4,279.65 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $3,824.64 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $3,348.64 | 2019-2025 | Dupixent, Libtayo |
| Galderma Research & Development, LLC | $2,975.00 | 2023 | |
| Arcutis Biotherapeutics, INC. | $2,202.44 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $2,140.81 | 2019-2025 | Taltz, Olumiant, Ebglyss |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,563.17 | 2019-2025 | |
| Incyte Corporation | $1,529.75 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,330.26 | 2019-2025 | Siliq, Duobrii, Arazlo |
| Janssen Biotech, INC. | $951.37 | 2020-2025 | Stelara, Simponi Aria, Simponi |
| Dermavant Sciences, INC. | $609.81 | 2022-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $331.42 | 2019-2025 | |
| Organon LLC | $272.78 | 2025 | Vtama, Nexplanon |
| Regeneron Pharmaceuticals, INC. | $160.88 | 2022 | |
| Epi Health, LLC | $95.48 | 2021 | |
| Almirall LLC | $78.27 | 2019-2022 | |
| Genentech USA, INC. | $43.63 | 2022-2024 | Xolair |
| Journey Medical Corporation | $39.32 | 2025 | |
| Mylan Pharmaceuticals INC. | $37.65 | 2019 | |
| Aclaris Therapeutics, INC. | $33.98 | 2019 | |
| Ani Pharmaceuticals, INC. | $31.30 | 2025 | Purified Cortrophin Gel |
| Revance Therapeutics, INC. | $25.37 | 2024 | Daxxify |
| Vyne Pharmaceuticals INC. | $18.52 | 2020 | |
| Merck Sharp & Dohme LLC | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Fujita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.